×
About 1,973 results

ALLMedicine™ Hyperoxaluria Center

Research & Reviews  961 results

Clinical characterization of primary hyperoxaluria type 3 in comparison to types 1 and ...
https://doi.org/10.1093/ndt/gfab027
Nephrology, Dialysis, Transplantation : Official Publicat... Singh P, Viehman JK et. al.

Feb 5th, 2021 - Primary hyperoxaluria type 3 (PH3) is caused by mutations in the HOGA1 gene. PH3 patients often present with recurrent urinary stone disease (USD) in first decade of life, but prior reports suggested PH3 may have a milder phenotype in adults. The ...

New Drugs for Rare Disorders.
https://doi.org/10.1097/01.NAJ.0000734120.60377.79
The American Journal of Nursing; Aschenbrenner DS

Jan 26th, 2021 - Several new drugs have been approved to treat rare genetic disorders: setmelanotide for certain conditions causing obesity; lumasiran for primary hyperoxaluria type 1, a kidney disorder; and lonafarnib for two diseases that cause premature aging.

Generation and characterization of a novel rat model of primary hyperoxaluria type 1 wi...
https://doi.org/10.1152/ajprenal.00514.2020
American Journal of Physiology. Renal Physiology; Li Y, Zheng R et. al.

Jan 25th, 2021 - Primary hyperoxaluria type 1 (PH1) is a severe inherited disorder caused by a genetic defect in alanine-glyoxylate aminotransferase (AGXT) that results in recurrent urolithiasis and renal failure. Animal models that precisely reflect the human PH1...

Liver transplant as a curative treatment in a pediatric patient with classic homocystin...
https://doi.org/10.1002/ajmg.a.62076
American Journal of Medical Genetics. Part A REFERENCES; Kerkvliet SP, Rheault MN et. al.

Jan 14th, 2021 - We report a patient with homocystinuria and hyperoxaluria who was cured of homocystinuria-related disease following liver transplant. The patient was diagnosed with homocystinuria as a newborn and was treated with dietary modifications and supplem...

see more →

Guidelines  2 results

Primary hyperoxaluria Type 1: indications for screening and guidance for diagnosis and ...
https://doi.org/10.1093/ndt/gfs078
Nephrology, Dialysis, Transplantation : Official Publicat... Cochat P, Hulton SA et. al.

May 1st, 2012 - Primary hyperoxaluria Type 1 is a rare autosomal recessive inborn error of glyoxylate metabolism, caused by a deficiency of the liver-specific enzyme alanine:glyoxylate aminotransferase. The disorder results in overproduction and excessive urinary...

OXLUMO™ (lumasiran) - Dosing and Admin Guide
https://www.oxlumohcp.com

Use the dosing and admin guide to learn which dosing regimen is right for your patients. Review dosing and administration for OXLUMO

see more →

Drugs  1 results see all →

Clinicaltrials.gov  987 results

Clinical characterization of primary hyperoxaluria type 3 in comparison to types 1 and ...
https://doi.org/10.1093/ndt/gfab027
Nephrology, Dialysis, Transplantation : Official Publicat... Singh P, Viehman JK et. al.

Feb 5th, 2021 - Primary hyperoxaluria type 3 (PH3) is caused by mutations in the HOGA1 gene. PH3 patients often present with recurrent urinary stone disease (USD) in first decade of life, but prior reports suggested PH3 may have a milder phenotype in adults. The ...

New Drugs for Rare Disorders.
https://doi.org/10.1097/01.NAJ.0000734120.60377.79
The American Journal of Nursing; Aschenbrenner DS

Jan 26th, 2021 - Several new drugs have been approved to treat rare genetic disorders: setmelanotide for certain conditions causing obesity; lumasiran for primary hyperoxaluria type 1, a kidney disorder; and lonafarnib for two diseases that cause premature aging.

Generation and characterization of a novel rat model of primary hyperoxaluria type 1 wi...
https://doi.org/10.1152/ajprenal.00514.2020
American Journal of Physiology. Renal Physiology; Li Y, Zheng R et. al.

Jan 25th, 2021 - Primary hyperoxaluria type 1 (PH1) is a severe inherited disorder caused by a genetic defect in alanine-glyoxylate aminotransferase (AGXT) that results in recurrent urolithiasis and renal failure. Animal models that precisely reflect the human PH1...

Liver transplant as a curative treatment in a pediatric patient with classic homocystin...
https://doi.org/10.1002/ajmg.a.62076
American Journal of Medical Genetics. Part A REFERENCES; Kerkvliet SP, Rheault MN et. al.

Jan 14th, 2021 - We report a patient with homocystinuria and hyperoxaluria who was cured of homocystinuria-related disease following liver transplant. The patient was diagnosed with homocystinuria as a newborn and was treated with dietary modifications and supplem...

see more →

News  11 results

FDA Clears First Drug to Treat Ultra-Rare Metabolic Disorder
https://www.medscape.com/viewarticle/941520

Nov 23rd, 2020 - The US Food and Drug Administration (FDA) has approved lumasiran (Oxlumo, Alnylam Pharmaceuticals) subcutaneous injection to treat children and adults with primary hyperoxaluria type 1 (PH1), an ultra-rare genetic disorder that causes recurrent ki...

Urinary Oxalate and CKD Progression: Is There an Association?
https://www.medscape.com/viewarticle/912061

May 1st, 2019 - Does higher urinary oxalate excretion predispose patients to kidney failure? Elevated levels of oxalate, a metabolite eliminated through the kidney, can be toxic. Oxalate nephropathy is characterized by high concentrations of oxalate in kidney tub...

FDA Approves First Drug to Treat Rare Metabolic Disorder
http://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-rare-metabolic-disorder

For Immediate Release: November 23, 2020 Today, the U.S. Food and Drug Administration approved Oxlumo (lumasiran) as the first treatment for primary hyperoxaluria type 1 (PH1), a rare genetic disorder. This approval is a cumulation of the work of ...

see more →

Patient Education  11 results see all →